PhillyPharma Archive: June, 2012

Johnson & Johnson to close Synthes deal Thursday for $19.7 billion

Comment icon 0 Comments
Johnson & Johnson said Tuesday evening it plans to complete the largest acquisition in company history, the takeover of medical device... Read more

Risperdal litigation costs growing for Johnson & Johnson

Comment icon 0 Comments
The legal bill for Johnson & Johnson seems to be growing after Friday's announcement that it has set aside an extra $600 million to deal... Read more

FTC approves $21.3 billion J&J-Synthes deal, pending DePuy sale to Biomet

Comment icon 0 Comments
The U.S. Federal Trade Commission Monday approved Johnson & Johnson's $21.3 billion purchase of medical device maker Synthes, Inc., assuming... Read more

GSK extends tender offer for Human Genome Sciences shares

Comment icon 0 Comments
GlaxoSmithKline said Friday morning it has extended its tender offer to buy all of the outstanding shares of Human Genome Sciences for $13... Read more

Johnson & Johnson expects bigger federal fines in Risperdal investigation

Comment icon 0 Comments
Johnson & Johnson said late Friday afternoon that it increased to $600 million the amount of money it has set aside to pay the civil fines... Read more

Pfizer to spin off its animal health unit, calling it Zoetis

Comment icon 0 Comments
Pfizer said Thursday morning that it would spin off its animal health unit and call the standalone company Zoetis. However, Pfizer will maintain... Read more

Recall of Introvale birth control pills

Comment icon 0 Comments
Some packages of the birth control pill Introvale were filled improperly, prompting a recall of 10 lots the drug, so that women are not impacted... Read more

With J&J deal pending, Synthes gives provisional notice of stock delisting

Comment icon 0 Comments
Synthes, Inc., the medical device manufacturer with headquarters in West Chester that is being bought by Johnson & Johnson, said in a statement... Read more